EYPT Quote, Financials, Valuation and Earnings

Cellectar Biosciences, Inc. has a net margin of -10904.68% compared to EyePoint Plc's net margin of --. EyePoint Plc's return on equity of -83.61% beat Cellectar Biosciences, Inc.'s return on equity of -209.22%.

EyePoint Plc has a consensus price target of $37.42, signalling upside risk potential of 179.23%. On the other hand Cellectar Biosciences, Inc. has an analysts' consensus of $33.33 which suggests that it could grow by 1207.19%. Given that Cellectar Biosciences, Inc. has higher upside potential than EyePoint Plc, analysts believe Cellectar Biosciences, Inc. is more attractive than EyePoint Plc.

EyePoint Plc has a beta of 1.891, which suggesting that the stock is 89.146% more volatile than S&P 500. In comparison Cellectar Biosciences, Inc. has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.123%.

EyePoint Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectar Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Plc pays -- of its earnings as a dividend. Cellectar Biosciences, Inc. pays out -- of its earnings as a dividend.

EyePoint Plc quarterly revenues are $620K, which are larger than Cellectar Biosciences, Inc. quarterly revenues of --. EyePoint Plc's net income of -$67.6M is lower than Cellectar Biosciences, Inc.'s net income of -$5.3M. Notably, EyePoint Plc's price-to-earnings ratio is -- while Cellectar Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Plc is 31.28x versus 137.94x for Cellectar Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ocular Therapeutix, Inc. has a net margin of -10904.68% compared to EyePoint Plc's net margin of -487.96%. EyePoint Plc's return on equity of -83.61% beat Ocular Therapeutix, Inc.'s return on equity of -73.88%.

EyePoint Plc has a consensus price target of $37.42, signalling upside risk potential of 179.23%. On the other hand Ocular Therapeutix, Inc. has an analysts' consensus of $26.00 which suggests that it could grow by 206.24%. Given that Ocular Therapeutix, Inc. has higher upside potential than EyePoint Plc, analysts believe Ocular Therapeutix, Inc. is more attractive than EyePoint Plc.

EyePoint Plc has a beta of 1.891, which suggesting that the stock is 89.146% more volatile than S&P 500. In comparison Ocular Therapeutix, Inc. has a beta of 0.955, suggesting its less volatile than the S&P 500 by 4.517%.

EyePoint Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Plc pays -- of its earnings as a dividend. Ocular Therapeutix, Inc. pays out -- of its earnings as a dividend.

EyePoint Plc quarterly revenues are $620K, which are smaller than Ocular Therapeutix, Inc. quarterly revenues of $13.3M. EyePoint Plc's net income of -$67.6M is lower than Ocular Therapeutix, Inc.'s net income of -$64.7M. Notably, EyePoint Plc's price-to-earnings ratio is -- while Ocular Therapeutix, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Plc is 31.28x versus 31.24x for Ocular Therapeutix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -10904.68% compared to EyePoint Plc's net margin of 21.74%. EyePoint Plc's return on equity of -83.61% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

EyePoint Plc has a consensus price target of $37.42, signalling upside risk potential of 179.23%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $872.70 which suggests that it could grow by 14.55%. Given that EyePoint Plc has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe EyePoint Plc is more attractive than Regeneron Pharmaceuticals, Inc..

EyePoint Plc has a beta of 1.891, which suggesting that the stock is 89.146% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.238%.

EyePoint Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.48% to investors and pays a quarterly dividend of $0.94 per share. EyePoint Plc pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

EyePoint Plc quarterly revenues are $620K, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. EyePoint Plc's net income of -$67.6M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, EyePoint Plc's price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Plc is 31.28x versus 5.66x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of -10904.68% compared to EyePoint Plc's net margin of 36.91%. EyePoint Plc's return on equity of -83.61% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.97%.

EyePoint Plc has a consensus price target of $37.42, signalling upside risk potential of 179.23%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $547.72 which suggests that it could grow by 24.85%. Given that EyePoint Plc has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe EyePoint Plc is more attractive than Vertex Pharmaceuticals, Inc..

EyePoint Plc has a beta of 1.891, which suggesting that the stock is 89.146% more volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.363, suggesting its less volatile than the S&P 500 by 63.664%.

EyePoint Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Plc pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

EyePoint Plc quarterly revenues are $620K, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.2B. EyePoint Plc's net income of -$67.6M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.2B. Notably, EyePoint Plc's price-to-earnings ratio is -- while Vertex Pharmaceuticals, Inc.'s PE ratio is 28.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Plc is 31.28x versus 9.19x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.